X

Trial Profile

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3325656 After Single Dose in Healthy Subjects and Patients With Type 2 Diabetes

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Jul 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LY 3325656 (Primary) ; Liraglutide; Sitagliptin
Indications Type 2 diabetes mellitus
Focus Adverse reactions
Sponsors Eli Lilly and Company

Most Recent Events

11 Jun 2019 Results assessing acute stimulatory effects of GPR142 on insulin and glucagon secretion, presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
22 Aug 2018 Status changed from recruiting to completed.
25 May 2018 Planned End Date changed from 1 Jun 2018 to 1 Jul 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com